| Literature DB >> 32161667 |
Shelby Rauh1, Trevor Torgerson1, Austin L Johnson1, Jonathan Pollard2, Daniel Tritz1, Matt Vassar1.
Abstract
BACKGROUND: The objective of this study was to evaluate the nature and extent of reproducible and transparent research practices in neurology publications.Entities:
Keywords: Cross-sectional; Neurology; Reproducibility; Transparency
Year: 2020 PMID: 32161667 PMCID: PMC7049215 DOI: 10.1186/s41073-020-0091-5
Source DB: PubMed Journal: Res Integr Peer Rev ISSN: 2058-8615
Reproducibility-related characteristics. Variable numbers (N) are dependent upon study design. Full detailed protocol pertaining to our measured variables is available online (https://osf.io/x24n3/)
| Indicators of reproducibility included in present study | Significance of measure variable for transparency and reproducibility | |
|---|---|---|
| Publications | ||
| All ( | Publication accessibility (Is the publication open access to the general public or accessible through a paywall?) | The general public’s ability to access scientific research may increase transparency of results and improve the ability for others to critically assess studies, potentially resulting in more replication studies |
| Funding | ||
| Included studies ( | Funding statement (Does the publication state their funding sources?) | Explicitly providing source of funding may help mitigate bias and potential conflicts of interest |
| Conflict of interest | ||
| Included studies ( | Conflict of interest statement (Does the publication state whether or not the authors had a conflict of interest?) | Explicitly providing conflicts of interest may allow for full disclosure of factors that may promote bias in the study design or outcomes |
| Publication citations | ||
| Empirical studiesa ( | Citations by a systematic review/meta-analysis (Has the publication been cited by any type of data synthesis publication, and if so, was it explicitly excluded?) | Systematic reviews and meta-analyses evaluate and compare existing literature to assess for patterns, strengths, and weaknesses of studies regarding a particular field or topic |
| Analysis scripts | ||
| Empirical studiesb ( | Availability statement (Does the publication state whether or not the analysis scripts are available?) | Providing access to the analysis script helps improve credibility by providing the replicators the opportunity to analyze raw data with the same analysis procedure |
| Method of availability (Ex: Are the analysis scripts available upon request or in a supplement?) | ||
| Accessibility (Can you view, download, or otherwise access the analysis scripts?) | ||
| Materials | ||
| Empirical studiesc ( | Availability statement (Does the publication state whether or not the materials are available?) | Providing the materials list allows replicators to reproduce study using the same materials, promoting |
| Method of availability (Ex: Are the materials available upon request or in a supplement?) | ||
| Accessibility (Can you view, download, or otherwise access the materials?) | ||
| Pre-registration | ||
| Empirical studiesb ( | Availability statement (Does the publication state whether or not it was pre-registered?) | Pre-registering studies may help mitigate potential bias and increase the overall validity and reliability of a study |
| Method of availability (Where was the publication pre-registered?) | ||
| Accessibility (Can you view or otherwise access the registration?) | ||
| Components (What components of the publication were pre-registered?) | ||
| Protocols | ||
| Empirical studiesb ( | Availability statement (Does the publication state whether or not a protocol is available?) | Providing replicators access to protocols allows for a more accurate replication of the study, promoting credibility |
| Components (What components are available in the protocol?) | ||
| Raw data | ||
| Empirical studiesb ( | Availability statement (Does the publication state whether or not the raw data are available?) | Providing replicators with access to raw data can help reduce potential bias and increase validity and reliability |
| Method of availability (Ex: Are the raw data available upon request or in a supplement?) | ||
| Accessibility (Can you view, download, or otherwise access the raw data?) | ||
| Components (Are all the necessary raw data to reproduce the study available?) | ||
| Clarity (Are the raw data documented clearly?) | ||
a“Empirical studies” are publications that include empirical data such as clinical trial, cohort, case series, case reports, case-control, secondary analysis, chart review, commentaries (with data analysis), laboratory, surveys, and cross-sectional designs
bEmpirical studies determined to be case reports or case series were excluded in regard to reproducibility related questions (materials, data, protocol, and registration were excluded) as recommended by Wallach et al.
cEmpirical studies determined to be either case reports, case series, commentaries with analysis, meta-analysis, or systematic review were excluded as they did not provide materials to fit the category
Fig. 1Flow diagram of included and excluded studies for the reproducibility analysis
Characteristics of included publications
| Characteristics | Variables | ||
|---|---|---|---|
| 95% CI | |||
| Funding, | University | 12 (3.1) | 1.4–4.8 |
| Hospital | 2 (0.5) | 0–1.2 | |
| Public | 79 (20.3) | 16.4–24.3 | |
| Private/industry | 17 (4.4) | 2.4–6.4 | |
| Non-profit | 15 (3.9) | 2.0–5.7 | |
| Mixed | 100 (25.7) | 21.4–30.0 | |
| No statement listed | 125 (32.1) | 27.6–36.7 | |
| No funding received | 39 (10.0) | 7.1–13.0 | |
| Type of study, | No empirical data | 98 (25.2) | 20.9–29.4 |
| Meta-analysis | 15 (3.9) | 2.0–5.7 | |
| Commentary with analysis | 1 (0.3) | 0–0.8 | |
| Cost-effectiveness | 2 (0.5) | 0–1.2 | |
| Clinical trial | 29 (7.5) | 4.9–10.0 | |
| Case study | 13 (3.3) | 1.6–5.1 | |
| Case series | 7 (1.8) | 0.5–3.1 | |
| Cohort | 54 (13.9) | 10.5–17.3 | |
| Chart review | 7 (1.8) | 0.5–3.1 | |
| Case control | 19 (4.9) | 2.8–7.0 | |
| Survey | 5 (1.3) | 0.2–2.4 | |
| Cross-sectional | 43 (11.1) | 8.0–14.1 | |
| Secondary analysis | 3 (0.8) | 0–1.6 | |
| Laboratory | 92 (23.7) | 19.5–17.8 | |
| Multiple study types | 1 (0.3) | 0–0.8 | |
| 5-year impact factor, | Median | 3.5 | – |
| 1st quartile | 2.6 | – | |
| 3rd quartile | 4.9 | – | |
| Interquartile range | 2.6–4.9 | – | |